Safety and Efficacy of Firmagon® (Degarelix) for Injection

An Extension Study Evaluating the Long-Term Safety and Tolerability of Degarelix One-Month Depots in Prostate Cancer

NCT00215683 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Treatment of Prostate Cancer With Firmagon®

NCT01710098 ·Status: COMPLETED

Firmagon (Degarelix) Intermittent Therapy

NCT01512472 ·Status: TERMINATED ·Phase: PHASE4

Intramuscular Injections of Degarelix Administered in 1-Month Dosing Regimens in Patients With Prostate Cancer

NCT01491971 ·Status: COMPLETED ·Phase: PHASE2

Study Investigating the Long-Term Safety and Tolerability of Repeated Doses of Degarelix in Prostate Cancer Patients

NCT00245466 ·Status: TERMINATED ·Phase: PHASE2

Extension Study Investigating the Long-Term Safety of Degarelix One-Month Depots in Patients With Prostate Cancer

NCT00117286 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Degarelix as Second-Line Hormonal Treatment After Prostate-specific Antigen (PSA)-Failure in GnRH Agonist Treated Patients With Prostate Cancer

NCT00738673 ·Status: COMPLETED ·Phase: PHASE2

Extension Study Investigating the Long-Term Safety and Tolerability of Repeat Doses of FE200486 in Prostate Cancer Patients

NCT00215657 ·Status: TERMINATED ·Phase: PHASE2

An Extension Long-term Safety and Tolerability Trial of Degarelix in Chinese Patients With Prostate Cancer

NCT02015871 ·Status: COMPLETED ·Phase: PHASE3

A Phase II Study of Degarelix in the Management of Non-Metastatic Hormone-Refractory Prostate Cancer

NCT01545882 ·Status: TERMINATED ·Phase: PHASE2

Extension Study Investigating the Long-Term Safety of Degarelix Three-Month Depots in Patients With Prostate Cancer

NCT00268892 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists

NCT01366053 ·Status: COMPLETED

Effectiveness and Safety of Firmagon® in Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma in Argentina

NCT01861236 ·Status: COMPLETED

A Trial to Evaluate Safety of Firmagon® (Degarelix) in Indian Patients Diagnosed With Advanced Hormone-dependent Prostate Cancer

NCT02726009 ·Status: COMPLETED ·Phase: PHASE4

Extension Study Investigating the Long-Term Safety and Tolerability of Repeat Doses of FE200486 in Prostate Cancer Patients

NCT00117312 ·Status: TERMINATED ·Phase: PHASE2

A Safety Study in Patients With Advanced Prostate Cancer Treated With FIRMAGON

NCT01234350 ·Status: COMPLETED

Pharmacokinetics of Degarelix in Chinese Patients With Prostate Cancer

NCT02468284 ·Status: COMPLETED ·Phase: PHASE1

Efficacy Study of Switching to a Lutenizing Hormone-releasing Hormone (LHRH) Antagonist From a LHRH Agonist to Treat Progressive Castrate Resistant Prostate Cancer (CRPC)

NCT01630967 ·Status: UNKNOWN ·Phase: PHASE2

Real-life Data of Cardiovascular Events Occuring During Degarelix Therapy for Prostate Cancer

NCT02229253 ·Status: COMPLETED

Study Investigating the Pharmacokinetics, Pharmacodynamics and Safety of FE200486

NCT00117949 ·Status: COMPLETED ·Phase: PHASE2

Androgen Deprivation Therapy Prior to Prostatectomy for Patients with Intermediate and High Risk Prostate Cancer

NCT01542021 ·Status: COMPLETED ·Phase: NA

A Parallel Group Comparison of the Efficacy and Safety of Degarelix at Two Different Dosing Regimens in Patients With Prostate Cancer

NCT00116779 ·Status: COMPLETED ·Phase: PHASE2

A Trial of Degarelix in Patients With Prostate Cancer

NCT00946920 ·Status: COMPLETED ·Phase: PHASE3

Investigation of a New Trial Drug (FE200486) in Prostate Cancer Patients

NCT00818623 ·Status: COMPLETED ·Phase: PHASE2

Degarelix Neo-Adjuvant Radical Prostatectomy Trial

NCT01674270 ·Status: COMPLETED ·Phase: PHASE2